Basic Information
INTRALIPID INFUSION 20%
INJECTION
Regulatory Information
SIN05269P
December 15, 1990
General Sale List
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XB05BA02
Company Information
FRESENIUS KABI (SINGAPORE) PTE LTD
FRESENIUS KABI (SINGAPORE) PTE LTD
Active Ingredients
Strength: 200 mg/ml
Detailed Information
Contraindications
**Contra-indications** INTRALIPID is contraindicated in patients with acute shock and those with severe disturbances in lipid metabolism such as pathologic hyperlipemia. INTRALIPID is also contraindicated in patients with severe liver insufficiency, hemophagocytotic syndrome, hypersensitivity to egg-, soya- or peanut protein or to any of the active substances or excipients. INTRALIPID also should not be used in patients with acute myocardial infarction until the condition has stabilized.
Indication Information
**Therapeutic Indications** INTRALIPID is indicated in patients needing intravenous nutrition to supply energy and essential fatty acids. INTRALIPID is also indicated in patients with essential fatty acid deficiency (EFAD) who cannot maintain or restore a normal essential fatty acid pattern by oral intake.